Clinical Trial Update: Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating selinexor in combination with an anti-PD-1 antibody and golidocitinib for relapsed/refractory extranodal natural killer/T-cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Natural Killer T-cell Lymphoma

Drugs mentioned

• Anti-PD-1 antibody
• Golidocitinib (golidocitinib)
• Selinexor (selinexor)

Snippet

Sponsor: Ruijin Hospital | Conditions: Lymphoma, Extranodal NK-T-Cell | Phase 2 | Status: NOT_YET_RECRUITING